Pecavaptan

DB16279InvestigationalSmall molecule

Pecavaptan is under investigation in clinical trial NCT03901729 (A Trial to Study BAY1753011 in Patients With Congestive Heart Failure).

Mechanism: Pharmacologically active on Vasopressin V1a receptor and Vasopressin V2 receptor
Curator reviewed
Formula / weight: C₂₂H₁₉Cl₂F₃N₆O₃ · 543.33 g/mol (avg)
Code names: BAY-1753011

Resolves to

Compound

Structure

InChIKeyAZXOTZCWQDJCLY-SJCJKPOMSA-NSMILESC[C@H](O)C1=NC(CN2N=C(N(C[C@H](O)C(F)(F)F)C2=O)C2=CC=C(Cl)C=C2)=NN1C1=CC(Cl)=CC=C1

Targets

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Pecavaptan, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.